Bank Julius Baer & Co
MRNA icon

Bank Julius Baer & Co’s Moderna MRNA Stock Holding History

Bank Julius Baer & Co’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.58M Sell
93,920
-31
-0% -$1.6K 0.02% 233
2026
Q1 		$4.77M Sell
93,951
-5,528
-6% -$258K 0.01% 238
2025
Q4 		$2.93M Sell
99,479
-119
-0.1% -$3.23K 0.01% 278
2025
Q3 		$2.57M Sell
99,598
-5,114
-5% -$143K 0.01% 307
2025
Q2 		$2.89M Sell
104,712
-811
-0.8% -$21.4K 0.01% 286
2025
Q1 		$2.99M Buy
105,523
+7,254
+7% +$257K 0.01% 270
2024
Q4 		$4.51M Sell
98,269
-86,321
-47% -$4.13M 0.01% 245
2024
Q3 		$14.2M Sell
184,590
-15,102
-8% -$1.39M 0.05% 162
2024
Q2 		$25.9M Sell
199,692
-34,132
-15% -$4.32M 0.1% 105
2024
Q1 		$25M Buy
233,824
+28,800
+14% +$2.9M 0.1% 114
2023
Q4 		$20.4M Buy
205,024
+71,941
+54% +$6.05M 0.09% 134
2023
Q3 		$13.7M Sell
133,083
-9,678
-7% -$1.08M 0.08% 131
2023
Q2 		$17.3M Sell
142,761
-2,244
-2% -$299K 0.1% 121
2023
Q1 		$22.3M Sell
145,005
-3,207
-2% -$529K 0.14% 111
2022
Q4 		$26.6M Sell
148,212
-6,460
-4% -$1.06M 0.18% 102
2022
Q3 		$18.3M Sell
154,672
-42,365
-22% -$6.43M 0.14% 108
2022
Q2 		$28.1M Sell
197,037
-10,001
-5% -$1.43M 0.2% 90
2022
Q1 		$35.7M Sell
207,038
-12,542
-6% -$2.11M 0.21% 81
2021
Q4 		$55.8M Sell
219,580
-4,242
-2% -$1.24M 0.3% 65
2021
Q3 		$86.1M Sell
223,822
-45,895
-17% -$16.9M 0.53% 47
2021
Q2 		$63.4M Buy
269,717
+4,764
+2% +$851K 0.4% 55
2021
Q1 		$34.7M Sell
264,953
-144,782
-35% -$21M 0.26% 83
2020
Q4 		$42.8M Buy
409,735
+12,404
+3% +$1.25M 0.35% 59
2020
Q3 		$28.1M Sell
397,331
-135,810
-25% -$9.47M 0.27% 74
2020
Q2 		$34.2M Sell
533,141
-258,938
-33% -$14.2M 0.39% 57
2020
Q1 		$23.7M Buy
+792,079
New +$18.2M 0.55% 52

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Bank Julius Baer & Co's MRNA Position: Q2 2026 in Review

Bank Julius Baer & Co reduced its Moderna (MRNA) stake by 0.03% in Q2 2026, selling an estimated $1.6K and leaving 93,920 shares worth $6.58M. The position accounts for 0.02% of the portfolio, ranked #233.

Bank Julius Baer & Co first reported a position in MRNA in Q1 2020 and has held it in 26 quarters since. The position peaked at $86.1M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Bank Julius Baer & Co held 93,920 shares of Moderna worth $6.58M as of Q2 2026.
  • Bank Julius Baer & Co sold 31 Moderna shares in Q2 2026, an estimated $1.6K.
  • Moderna made up 0.02% of Bank Julius Baer & Co's portfolio in Q2 2026, its #233 holding.
  • Bank Julius Baer & Co first reported a position in Moderna in Q1 2020 and has held it in 26 quarters since.
  • Bank Julius Baer & Co's Moderna position peaked at $86.1M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Bank Julius Baer & Co's 13F filing for Q2 2026, filed 10 Aug 2026.